5772 studies found for:    breast,cancer,treatment
Show Display Options
Rank Status Study
1 Active, not recruiting Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
Conditions: Breast Cancer;   Cancer of the Breast;   Neoplasms, Breast
Intervention: Drug: Estrace followed by anastrazole
2 Completed Understanding Shared Psychobiological Pathways
Condition: Breast Neoplasms
Interventions: Behavioral: Education;   Behavioral: Peer support
3 Active, not recruiting Hula, a Physical Activity Intervention for Breast Cancer Survivors
Conditions: Physical Activity;   Breast Cancer
Intervention: Behavioral: Hula
4 Recruiting A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Condition: Vaginal Atrophy
Interventions: Drug: estriol;   Drug: Placebo
5 Unknown  Stress Management in Breast Cancer Patients
Conditions: Breast Cancer;   Stress
Intervention: Behavioral: Stress management, in two steps
6 Active, not recruiting Cognitive Changes Associated With Breast Cancer Treatment
Conditions: Breast Cancer;   Cognitive Side Effects of Cancer Treatments;   Stage I, II and III A Breast Cancer
Intervention: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
7 Active, not recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
8 Completed Predictive Model of Therapy Outcomes in Breast Cancer Patients
Condition: Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.
Intervention:
9 Active, not recruiting Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation
Condition: Cancer of the Breast
Interventions: Procedure: Surgery for breast cancer;   Other: No Loco-regional treatment
10 Completed
Has Results
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
Conditions: Breast Cancer;   Dermatologic Complications;   Radiation Toxicity;   Skin Reactions Secondary to Radiation Therapy
Interventions: Drug: mometasone furoate;   Other: placebo
11 Active, not recruiting Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Multi-Beam Intensity-Modulated Radiation Therapy
12 Completed Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
Conditions: Breast Cancer;   Cancer Survivor;   Fatigue;   Long-term Effects Secondary to Cancer Therapy in Adults;   Psychosocial Effects of Cancer and Its Treatment
Interventions: Behavioral: exercise intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
13 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
14 Completed Breast Cancer With Over-expression of erbB2-BRAINSTORM
Condition: Cancer
Intervention: Drug: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
15 Terminated Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Other: Genomic and Proteomic Profiling
16 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
17 Active, not recruiting Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Condition: Breast Cancer
Interventions: Radiation: Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy;   Radiation: Higher per daily radiation therapy;   Radiation: Concurrent boost radiotherapy;   Radiation: Standard per daily radiation therapy;   Radiation: Sequential boost radiotherapy
18 Completed Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Procedure: adjuvant therapy
19 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
20 Terminated Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
Conditions: Breast Cancer;   Cognitive/Functional Effects;   Colorectal Cancer;   Psychosocial Effects of Cancer and Its Treatment
Interventions: Behavioral: compliance monitoring;   Drug: systemic chemotherapy;   Other: medical chart review;   Other: study of socioeconomic and demographic variables;   Other: survey administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years